Related Experiment Videos

[Is regression of coronary sclerosis possible?]

H P Krayenbühl1

  • 1Departement für Innere Medizin, Universitätsspital Zürich.

Schweizerische Rundschau Fur Medizin Praxis = Revue Suisse De Medecine Praxis
|November 23, 1993
PubMed

Insights

Aggressive lipid-lowering therapy and lifestyle changes can slow or reverse coronary artery lesions. These interventions also reduce clinical events, while certain calcium blockers prevent new stenoses.

Area of Science:

  • Cardiovascular Medicine
  • Interventional Cardiology
  • Preventive Cardiology

Context:

  • Coronary artery disease (CAD) progression and regression are key indicators of cardiovascular health.
  • Sequential coronary arteriography provides objective measures of lesion changes.
  • Lipid management and lifestyle modifications are central to CAD treatment strategies.

Purpose:

  • To evaluate the impact of aggressive lipid-lowering therapy and lifestyle changes on coronary artery lesions.
  • To determine the relationship between achieved cholesterol and LDL cholesterol levels and lesion modification.
  • To assess the effect of specific calcium channel blockers (nifedipine, nicardipine) on stenosis development.

Summary:

  • Randomized studies demonstrate that aggressive lipid-lowering therapy and lifestyle changes can reduce the progression and induce modest regression of coronary artery lesions.
  • The degree of lesion change is directly related to the achieved levels of cholesterol and low-density lipoprotein (LDL) cholesterol.
  • Three studies confirmed that lipid-lowering interventions not only improve arteriographic lesions but also decrease clinical events.
  • Calcium blockers like nifedipine and nicardipine do not affect lesion progression or regression but reduce the formation of new coronary stenoses.

Impact:

  • Aggressive lipid management and lifestyle interventions are effective in modifying coronary atherosclerosis.
  • Achieving lower cholesterol and LDL cholesterol targets is crucial for regression of coronary lesions.
  • These findings support the use of lipid-lowering therapies to reduce both arteriographic disease burden and clinical cardiovascular events.
  • Specific calcium channel blockers may play a role in preventing the development of new coronary artery blockages.

Related Concept Videos